MAYNE PHARMA ANNOUNCES FDA APPROVAL OF MITOXANTRONE

A A

Mayne Pharma has announced that the FDA has granted final approval for the company's abbreviated new drug application for Mitoxantrone injection in 20 mg, 25 mg and 30 mg multiple-dose formulations.

Mitoxantrone is a generic equivalent to Serono's multiple sclerosis drug Novantrone.